Deep Profiling of Protease Substrate Specificity Enabled by Dual Random and Scanned Human Proteome Substrate Phage Libraries
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The ELIXIR Core Data Resources: Fundamental Infrastructure for The
Supplementary Data: The ELIXIR Core Data Resources: fundamental infrastructure for the life sciences The “Supporting Material” referred to within this Supplementary Data can be found in the Supporting.Material.CDR.infrastructure file, DOI: 10.5281/zenodo.2625247 (https://zenodo.org/record/2625247). Figure 1. Scale of the Core Data Resources Table S1. Data from which Figure 1 is derived: Year 2013 2014 2015 2016 2017 Data entries 765881651 997794559 1726529931 1853429002 2715599247 Monthly user/IP addresses 1700660 2109586 2413724 2502617 2867265 FTEs 270 292.65 295.65 289.7 311.2 Figure 1 includes data from the following Core Data Resources: ArrayExpress, BRENDA, CATH, ChEBI, ChEMBL, EGA, ENA, Ensembl, Ensembl Genomes, EuropePMC, HPA, IntAct /MINT , InterPro, PDBe, PRIDE, SILVA, STRING, UniProt ● Note that Ensembl’s compute infrastructure physically relocated in 2016, so “Users/IP address” data are not available for that year. In this case, the 2015 numbers were rolled forward to 2016. ● Note that STRING makes only minor releases in 2014 and 2016, in that the interactions are re-computed, but the number of “Data entries” remains unchanged. The major releases that change the number of “Data entries” happened in 2013 and 2015. So, for “Data entries” , the number for 2013 was rolled forward to 2014, and the number for 2015 was rolled forward to 2016. The ELIXIR Core Data Resources: fundamental infrastructure for the life sciences 1 Figure 2: Usage of Core Data Resources in research The following steps were taken: 1. API calls were run on open access full text articles in Europe PMC to identify articles that mention Core Data Resource by name or include specific data record accession numbers. -
PLK-1 Promotes the Merger of the Parental Genome Into A
RESEARCH ARTICLE PLK-1 promotes the merger of the parental genome into a single nucleus by triggering lamina disassembly Griselda Velez-Aguilera1, Sylvia Nkombo Nkoula1, Batool Ossareh-Nazari1, Jana Link2, Dimitra Paouneskou2, Lucie Van Hove1, Nicolas Joly1, Nicolas Tavernier1, Jean-Marc Verbavatz3, Verena Jantsch2, Lionel Pintard1* 1Programme Equipe Labe´llise´e Ligue Contre le Cancer - Team Cell Cycle & Development - Universite´ de Paris, CNRS, Institut Jacques Monod, Paris, France; 2Department of Chromosome Biology, Max Perutz Laboratories, University of Vienna, Vienna Biocenter, Vienna, Austria; 3Universite´ de Paris, CNRS, Institut Jacques Monod, Paris, France Abstract Life of sexually reproducing organisms starts with the fusion of the haploid egg and sperm gametes to form the genome of a new diploid organism. Using the newly fertilized Caenorhabditis elegans zygote, we show that the mitotic Polo-like kinase PLK-1 phosphorylates the lamin LMN-1 to promote timely lamina disassembly and subsequent merging of the parental genomes into a single nucleus after mitosis. Expression of non-phosphorylatable versions of LMN- 1, which affect lamina depolymerization during mitosis, is sufficient to prevent the mixing of the parental chromosomes into a single nucleus in daughter cells. Finally, we recapitulate lamina depolymerization by PLK-1 in vitro demonstrating that LMN-1 is a direct PLK-1 target. Our findings indicate that the timely removal of lamin is essential for the merging of parental chromosomes at the beginning of life in C. elegans and possibly also in humans, where a defect in this process might be fatal for embryo development. *For correspondence: [email protected] Introduction Competing interests: The After fertilization, the haploid gametes of the egg and sperm have to come together to form the authors declare that no genome of a new diploid organism. -
DECIPHER: Harnessing Local Sequence Context to Improve Protein Multiple Sequence Alignment Erik S
Wright BMC Bioinformatics (2015) 16:322 DOI 10.1186/s12859-015-0749-z RESEARCH ARTICLE Open Access DECIPHER: harnessing local sequence context to improve protein multiple sequence alignment Erik S. Wright1,2 Abstract Background: Alignment of large and diverse sequence sets is a common task in biological investigations, yet there remains considerable room for improvement in alignment quality. Multiple sequence alignment programs tend to reach maximal accuracy when aligning only a few sequences, and then diminish steadily as more sequences are added. This drop in accuracy can be partly attributed to a build-up of error and ambiguity as more sequences are aligned. Most high-throughput sequence alignment algorithms do not use contextual information under the assumption that sites are independent. This study examines the extent to which local sequence context can be exploited to improve the quality of large multiple sequence alignments. Results: Two predictors based on local sequence context were assessed: (i) single sequence secondary structure predictions, and (ii) modulation of gap costs according to the surrounding residues. The results indicate that context-based predictors have appreciable information content that can be utilized to create more accurate alignments. Furthermore, local context becomes more informative as the number of sequences increases, enabling more accurate protein alignments of large empirical benchmarks. These discoveries became the basis for DECIPHER, a new context-aware program for sequence alignment, which outperformed other programs on largesequencesets. Conclusions: Predicting secondary structure based on local sequence context is an efficient means of breaking the independence assumption in alignment. Since secondary structure is more conserved than primary sequence, it can be leveraged to improve the alignment of distantly related proteins. -
(DDD) Project: What a Genomic Approach Can Achieve
The Deciphering Development Disorders (DDD) project: What a genomic approach can achieve RCP ADVANCED MEDICINE, LONDON FEB 5TH 2018 HELEN FIRTH DM FRCP DCH, SANGER INSTITUTE 3,000,000,000 bases in each human genome Disease & developmental Health & development disorders Fascinating facts about your genome! –~20,000 protein-coding genes –~30% of genes have a known role in disease or developmental disorders –~10,000 protein altering variants –~100 protein truncating variants –~70 de novo mutations (~1-2 coding ie. In exons of genes) Rare Disease affects 1 in 17 people •Prior to DDD, diagnostic success in patients with rare paediatric disease was poor •Not possible to diagnose many patients with current methodology in routine use– maximum benefit in this group •DDD recruited patients with severe/extreme clinical features present from early childhood with high expectation of genetic basis •Recruitment was primarily of trios (ie The Doctor Sir Luke Fildes (1887) child and both parents) ~ 90% Making a genomic diagnosis of a rare disease improves care •Accurate diagnosis is the cornerstone of good medical practice – informing management, treatment, prognosis and prevention •Enables risk to other family members to be determined enabling predictive testing with potential for surveillance and therapy in some disorders February 28th 2018 •Reduces sense of isolation, enabling better access to support and information •Curtails the diagnostic odyssey •Not just a descriptive label; identifies the fundamental cause of disease A genomic diagnosis can be a gateway to better treatment •Not just a descriptive label; identifies the fundamental cause of disease •Biallelic mutations in the CFTR gene cause Cystic Fibrosis • CFTR protein is an epithelial ion channel regulating absorption/ secretion of salt and water in the lung, sweat glands, pancreas & GI tract. -
Acetic Acid (Activator-3) Is a Potent Activator of AMPK
www.nature.com/scientificreports OPEN 2-[2-(4-(trifuoromethyl) phenylamino)thiazol-4-yl]acetic acid (Activator-3) is a potent Received: 29 June 2017 Accepted: 6 June 2018 activator of AMPK Published: xx xx xxxx Navneet Bung1, Sobhitha Surepalli2, Sriram Seshadri3, Sweta Patel3, Saranya Peddasomayajula2, Lalith Kumar Kummari 2,5,6, Sireesh T. Kumar4, Phanithi Prakash Babu4, Kishore V. L. Parsa2, Rajamohan Reddy Poondra2, Gopalakrishnan Bulusu1,2 & Parimal Misra2 AMPK is considered as a potential high value target for metabolic disorders. Here, we present the molecular modeling, in vitro and in vivo characterization of Activator-3, 2-[2-(4-(trifuoromethyl) phenylamino)thiazol-4-yl]acetic acid, an AMP mimetic and a potent pan-AMPK activator. Activator-3 and AMP likely share common activation mode for AMPK activation. Activator-3 enhanced AMPK phosphorylation by upstream kinase LKB1 and protected AMPK complex against dephosphorylation by PP2C. Molecular modeling analyses followed by in vitro mutant AMPK enzyme assays demonstrate that Activator-3 interacts with R70 and R152 of the CBS1 domain on AMPK γ subunit near AMP binding site. Activator-3 and C2, a recently described AMPK mimetic, bind diferently in the γ subunit of AMPK. Activator-3 unlike C2 does not show cooperativity of AMPK activity in the presence of physiological concentration of ATP (2 mM). Activator-3 displays good pharmacokinetic profle in rat blood plasma with minimal brain penetration property. Oral treatment of High Sucrose Diet (HSD) fed diabetic rats with 10 mg/kg dose of Activator-3 once in a day for 30 days signifcantly enhanced glucose utilization, improved lipid profles and reduced body weight, demonstrating that Activator-3 is a potent AMPK activator that can alleviate the negative metabolic impact of high sucrose diet in rat model. -
Annual Scientific Report 2013 on the Cover Structure 3Fof in the Protein Data Bank, Determined by Laponogov, I
EMBL-European Bioinformatics Institute Annual Scientific Report 2013 On the cover Structure 3fof in the Protein Data Bank, determined by Laponogov, I. et al. (2009) Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nature Structural & Molecular Biology 16, 667-669. © 2014 European Molecular Biology Laboratory This publication was produced by the External Relations team at the European Bioinformatics Institute (EMBL-EBI) A digital version of the brochure can be found at www.ebi.ac.uk/about/brochures For more information about EMBL-EBI please contact: [email protected] Contents Introduction & overview 3 Services 8 Genes, genomes and variation 8 Molecular atlas 12 Proteins and protein families 14 Molecular and cellular structures 18 Chemical biology 20 Molecular systems 22 Cross-domain tools and resources 24 Research 26 Support 32 ELIXIR 36 Facts and figures 38 Funding & resource allocation 38 Growth of core resources 40 Collaborations 42 Our staff in 2013 44 Scientific advisory committees 46 Major database collaborations 50 Publications 52 Organisation of EMBL-EBI leadership 61 2013 EMBL-EBI Annual Scientific Report 1 Foreword Welcome to EMBL-EBI’s 2013 Annual Scientific Report. Here we look back on our major achievements during the year, reflecting on the delivery of our world-class services, research, training, industry collaboration and European coordination of life-science data. The past year has been one full of exciting changes, both scientifically and organisationally. We unveiled a new website that helps users explore our resources more seamlessly, saw the publication of ground-breaking work in data storage and synthetic biology, joined the global alliance for global health, built important new relationships with our partners in industry and celebrated the launch of ELIXIR. -
Understanding the Structure and Function of Catalases: Clues from Molecular Evolution and in Vitro Mutagenesis
PERGAMON Progress in Biophysics & Molecular Biology 72 (1999) 19±66 Understanding the structure and function of catalases: clues from molecular evolution and in vitro mutagenesis Marcel Za mocky *, Franz Koller Institut fuÈr Biochemie and Molekulare Zellbiologie and Ludwig Boltzmann Forschungsstelle fuÈr Biochemie, Vienna Biocenter, Dr. Bohr-Gasse 9, A-1030 Wien, Austria Abstract This review gives an overview about the structural organisation of dierent evolutionary lines of all enzymes capable of ecient dismutation of hydrogen peroxide. Major potential applications in biotechnology and clinical medicine justify further investigations. According to structural and functional similarities catalases can be divided in three subgroups. Typical catalases are homotetrameric haem proteins. The three-dimensional structure of six representatives has been resolved to atomic resolution. The central core of each subunit reveals a chracteristic ``catalase fold'', extremely well conserved among this group. In the native tetramer structure pairs of subunits tightly interact via exchange of their N- terminal arms. This pseudo-knot structures implies a highly ordered assembly pathway. A minor subgroup (``large catalases'') possesses an extra ¯avodoxin-like C-terminal domain. A r25AÊ long channel leads from the enzyme surface to the deeply buried active site. It enables rapid and selective diusion of the substrates to the active center. In several catalases NADPH is tightly bound close to the surface. This cofactor may prevent and reverse the formation of compound II, an inactive reaction intermediate. Bifunctional catalase-peroxidases are haem proteins which probably arose via gene duplication of an ancestral peroxidase gene. No detailed structural information is currently available. Even less is know about manganese catalases. -
Global Cellular Response to Chemotherapy- Induced
RESEARCH ARTICLE elife.elifesciences.org Global cellular response to chemotherapy- induced apoptosis Arun P Wiita1,2, Etay Ziv3,4, Paul J Wiita5, Anatoly Urisman1,6, Olivier Julien1, Alma L Burlingame1, Jonathan S Weissman3,7, James A Wells1,3* 1Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States; 2Department of Laboratory Medicine, University of California, San Francisco, San Francisco, United States; 3Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States; 4Department of Radiology, University of California, San Francisco, San Francisco, United States; 5Department of Physics, The College of New Jersey, Ewing, United States; 6Department of Pathology, University of California, San Francisco, San Francisco, United States; 7Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, United States Abstract How cancer cells globally struggle with a chemotherapeutic insult before succumbing to apoptosis is largely unknown. Here we use an integrated systems-level examination of transcription, translation, and proteolysis to understand these events central to cancer treatment. As a model we study myeloma cells exposed to the proteasome inhibitor bortezomib, a first-line therapy. Despite robust transcriptional changes, unbiased quantitative proteomics detects production of only a few critical anti-apoptotic proteins against a background of general translation inhibition. Simultaneous ribosome profiling further reveals potential translational regulation of stress response genes. Once the apoptotic machinery is engaged, degradation by caspases is largely independent of upstream bortezomib effects. Moreover, previously uncharacterized non-caspase proteolytic events also participate in cellular deconstruction. Our systems-level data also support co-targeting the anti-apoptotic regulator HSF1 to promote cell death by bortezomib. -
Human Genome Sequence 2/3 Complete
Human Genome Sequence 2/3 Complete March 29, 2000 Two Thirds of Human DNA Script Deciphered by Human Genome Project; Public Consortium To Complete “Working Draft” in June The Human Genome Project international consortium announced today that two billion of the three billion “letters” that constitute the genetic instruction book of humans have been deciphered and deposited into GenBank. GenBank, the public database of DNA sequence operated by the National Institutes of Health, is accessible freely and without restrictions to all scientists in industry and academia. The two billionth “letter,” or base pair, was deposited earlier this month by the Wellcome Trust’s Sanger Centre in Great Britain. The “letter” was a “T,” the abbreviation for thymine, one of the four chemicals or bases that make up DNA. The 2,178,076,000 unique base pairs now in GenBank have been mapped to their locations on the 24 human chromosomes. The Human Genome Project is on track to complete the “working draft,” which will include 90 percent of the human DNA sequence, with an accuracy of 99.9 percent, in June. The Human Genome Project worldwide will invest an estimated $250 million in producing the working draft. The finished, stand-the-test of time version of the human DNA sequence will be ready on or before 2003. Just four months ago, the Human Genome Project reached the one-billionth base pair milestone. “It’s good news that we’re moving so fast but it’s even better news that researchers throughout the world are using this data now to investigate the genetic underpinnings of health and diseases ranging from Alzheimer’s to diabetes,” said Dr. -
Drug Conjugates Based on a Monovalent Affibody Targeting
cancers Article Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model Tianqi Xu 1,† , Haozhong Ding 2,† , Anzhelika Vorobyeva 1,3 , Maryam Oroujeni 1, Anna Orlova 3,4 , Vladimir Tolmachev 1,3 and Torbjörn Gräslund 2,* 1 Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden; [email protected] (T.X.); [email protected] (A.V.); [email protected] (M.O.); [email protected] (V.T.) 2 Department of Protein Science, KTH Royal Institute of Technology, Roslagstullsbacken 21, 114 17 Stockholm, Sweden; [email protected] 3 Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia; [email protected] 4 Department of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden * Correspondence: [email protected]; Tel.: +46-(0)8-790-96-27 † Equal contribution. Simple Summary: Drug conjugates, consisting of a tumor targeting part coupled to a highly toxic molecule, are promising for treatment of many different types of cancer. However, for many patients it is not curative, and investigation of alternative or complimentary types of drug conjugates is motivated. Here, we have devised and studied a novel cancer cell-directed drug conjugate ZHER2:2891- ABD-E3-mcDM1. We found that it could induce efficient shrinkage and, in some cases, complete Citation: Xu, T.; Ding, H.; Vorobyeva, regression of human tumors implanted in mice, and thus holds promise to become a therapeutic A.; Oroujeni, M.; Orlova, A.; agent for clinical use in the future. -
Strategic Plan 2011-2016
Strategic Plan 2011-2016 Wellcome Trust Sanger Institute Strategic Plan 2011-2016 Mission The Wellcome Trust Sanger Institute uses genome sequences to advance understanding of the biology of humans and pathogens in order to improve human health. -i- Wellcome Trust Sanger Institute Strategic Plan 2011-2016 - ii - Wellcome Trust Sanger Institute Strategic Plan 2011-2016 CONTENTS Foreword ....................................................................................................................................1 Overview .....................................................................................................................................2 1. History and philosophy ............................................................................................................ 5 2. Organisation of the science ..................................................................................................... 5 3. Developments in the scientific portfolio ................................................................................... 7 4. Summary of the Scientific Programmes 2011 – 2016 .............................................................. 8 4.1 Cancer Genetics and Genomics ................................................................................ 8 4.2 Human Genetics ...................................................................................................... 10 4.3 Pathogen Variation .................................................................................................. 13 4.4 Malaria -
Comparative Genomics of the Major Parasitic Worms
Comparative genomics of the major parasitic worms International Helminth Genomes Consortium Supplementary Information Introduction ............................................................................................................................... 4 Contributions from Consortium members ..................................................................................... 5 Methods .................................................................................................................................... 6 1 Sample collection and preparation ................................................................................................................. 6 2.1 Data production, Wellcome Trust Sanger Institute (WTSI) ........................................................................ 12 DNA template preparation and sequencing................................................................................................. 12 Genome assembly ........................................................................................................................................ 13 Assembly QC ................................................................................................................................................. 14 Gene prediction ............................................................................................................................................ 15 Contamination screening ............................................................................................................................